Press Releases

18 Dec 2014The Medicines Company and SciClone Pharmaceuticals Establish Strategic Partnership for Two Cardiovascular Products in China12 Dec 2014Technical Data on Pharma Stocks - Pfizer, Merck, AbbVie, Akorn, and The Medicines11 Dec 2014Alnylam and The Medicines Company Announce Initiation of Phase 1 Clinical Trial for ALN-PCSsc, a Subcutaneously Administered Investigational RNAi Therapeutic Targeting PCSK9 for the Treatment of Hypercholesterolemia08 Dec 2014The Medicines Company to Participate in Oppenheimer 25th Annual Healthcare Conference16 Nov 2014The Medicines Company Presents New Phase 1 Data Showing Investigational Agent MDCO-216 Modified Key Lipid Parameters and Was Well-Tolerated in Healthy and Coronary Artery Disease (CAD) Patients14 Nov 2014The Medicines Company to Present New Data on Investigational Lipid-Modifying Agent MDCO-216 and Investigational Antiplatelet Agent Cangrelor at 2014 American Heart Association (AHA) Annual Scientific Sessions in Chicago11 Nov 2014The Medicines Company to Participate in Credit Suisse Healthcare Conference07 Nov 2014Health Economic Data on The Medicines Company’s Infectious Disease and Cardiology Portfolios to be Presented at the 17th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR)05 Nov 2014The Medicines Company Announces First Patient Enrollment in Phase 3 Studies of CARBAVANCE™ in Development for the Treatment of Serious Bacterial Infections Due to Gram-Negative Bacteria04 Nov 2014Update to The Medicines Company Investor & Analyst Day on November 530 Oct 2014The Medicines Company to Webcast Investor & Analyst Day on November 528 Oct 2014The Medicines Company Wins Favorable Judgment in Angiomax® (Bivalirudin) Patent Litigation28 Oct 2014The Medicines Company Announces Presentation of Investigational Hemostatic Agent RAPLIXA™ (fibrin sealant) Phase III FINISH-3 Trial Results at the 2014 Clinical Conference of the American College of Surgeons24 Oct 2014The Medicines Company Announces Participation in 2014 American College of Emergency Physicians Scientific Assembly22 Oct 2014The Medicines Company Reports Third Quarter and First Nine Months 2014 Results09 Oct 2014ORBACTIVTM (Oritavancin) Phase 3 SOLO II Trial Results Published in the Journal Clinical Infectious Diseases08 Oct 2014The Medicines Company to Announce Third Quarter 2014 Financial Results on Wednesday, October 22, 201406 Oct 2014The Medicines Company Infectious Disease Portfolio Data to Be Presented at ID Week 201423 Sep 2014The Medicines Company to Webcast Infectious Disease Care Investor & Analyst Day on September 2412 Sep 2014The Medicines Company to Review ORBACTIVTM (oritavancin) Launch Readiness on Tuesday, September 16, 201427 Aug 2014The Medicines Company to Present New Data from its Infectious Disease Portfolio at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)07 Aug 2014The Medicines Company and Alnylam Pharmaceuticals to Host RNAi Roundtable Webcast “ALN-PCSsc for the Treatment of Hypercholesterolemia”07 Aug 2014FDA Approves The Medicines Company's ORBACTIV™ (oritavancin) for Use in Acute Bacterial Skin and Skin Structure Infections04 Aug 2014The Medicines Company to Host Infectious Disease Care Investor and Analyst Meeting on September 24, 201423 Jul 2014The Medicines Company Reports Second Quarter and First Half 2014 Results14 Jul 2014Upcoming Conference Calls, FDA Approvals, NDA Updates, and Donations - Analyst Notes on The Medicines Company, Bio-Rad, Spectrum Pharmaceuticals, Insys Therapeutics and Hanger09 Jul 2014The Medicines Company to Announce Second Quarter and First Half 2014 Financial Results on Wednesday, July 23, 201407 Jul 2014The Medicines Company Receives Market Authorization Renewal for Angiox® (Bivalirudin) from the European Medicines Agency and the European Commission05 Jun 2014ORBACTIVTM (Oritavancin) Phase 3 Trial Results Published in New England Journal of Medicine04 Jun 2014The Medicines Company to Participate in Goldman Sachs 35th Annual Global Healthcare Conference04 Jun 2014The Medicines Company Presents Seven Hospital Data Analyses at Leading Health Economics and Outcomes Research Conferences29 May 2014Critical Alerts For Microsoft, Medicines, LinkedIn, Priceline, and Qihoo 360 Technology Released By InvestorsObserver27 May 2014The Medicines Company to Participate in 2014 Jefferies Global Healthcare Conference22 May 2014Data on Angiox (Bivalirudin Injection) in Heart Attack Patients Presented at EuroPCR and Published in European Heart Journal08 May 2014The Medicines Company to Host Surgery and Perioperative Care Investor and Analyst Meeting on May 2206 May 2014The Medicines Company to Participate in 2014 Bank of America Global Healthcare Conference01 May 2014The Medicines Company and Alnylam Announce Presentation of New Pre-Clinical Data on PCSK9 at Arteriosclerosis, Thrombosis and Vascular Biology 2014 Scientific Sessions30 Apr 2014The Medicines Company Receives Complete Response Letter From FDA Requesting Additional Information for New Drug Application for Its Antiplatelet Agent Cangrelor25 Apr 2014Critical Alerts For American Express, Time Warner, Nasdaq OMX Group, The Medicines Company, and PetSmart By InvestorsObserver23 Apr 2014The Medicines Company Adds Novel, Approved, Surgical Sealant to Its Surgical Hemostasis Portfolio23 Apr 2014The Medicines Company Reports First Quarter 2014 Financial Results18 Apr 2014SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against The Medicines Company and Certain Officers - MDCO10 Apr 2014INVESTOR ALERT: Glancy Binkow & Goldberg LLP Reminds Investors of the Lead Plaintiff Deadline in the Class Action Lawsuit Against The Medicines Company10 Apr 2014UPCOMING DEADLINE: Levi & Korsinsky, LLP Notifies Investors of Class Action Against THE MEDICINES COMPANY and Its Board of Directors and a Lead Plaintiff Deadline of April 22, 201409 Apr 2014The Medicines Company to Announce First Quarter 2014 Financial Results on Wednesday, April 23, 201403 Apr 2014FDA Accepts the Filing of The Medicines Company's US Biologic License Application for Fibrocaps Hemostatic Agent02 Apr 2014THE MEDICINES COMPANY SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $150,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against The Medicines Company - MDCO01 Apr 2014Update on Angiomax(R) (Bivalirudin) Patent Litigation01 Apr 2014INVESTOR ALERT: Law Offices of Howard G. Smith Announces Lead Plaintiff Deadline In The Class Action Lawsuit Against The Medicines Company30 Mar 2014Analysis of EUROMAX and HORIZONS-AMI Trials of The Medicines Company's Angiomax(R) (Bivalirudin) Presented at ACC.1426 Mar 2014SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of Class Action Against THE MEDICINES COMPANY and Its Board of Directors and a Lead Plaintiff Deadline of April 22, 201421 Mar 2014SHAREHOLDERS ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against The Medicines Company and Certain Officers - MDCO18 Mar 2014The Medicines Company Shareholder Alert: Former SEC Attorney Willie Briscoe and Powers Taylor Investigate Possible Breaches of Fiduciary Duty by Officers and Directors16 Mar 2014/ CORRECTION - Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In The Medicines Company To Contact The Firm15 Mar 2014Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses in Excess of $100,000 Investing in The Medicines Company to Contact the Firm14 Mar 2014Cohen Milstein Sellers & Toll PLLC Announces the Investigation of The Medicines Company11 Mar 2014THE MEDICINES COMPANY SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of Class Action Against THE MEDICINES COMPANY and Its Board of Directors and a Lead Plaintiff Deadline of April 22, 2014 -- MDCO06 Mar 2014The Medicines Company to Participate in 2014 Barclays Global Healthcare Conference06 Mar 2014THE MEDICINES COMPANY SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of Class Action Against THE MEDICINES COMPANY and Its Board of Directors and a Lead Plaintiff Deadline of April 22, 2014 -- MDCO04 Mar 2014INVESTOR ALERT: Class Action Lawsuit Against The Medicines Company Announced by Law Offices of Howard G. Smith03 Mar 2014Attention The Medicines Company Investors: The Medicines Company Misled Investors According to a Recently Filed Class Action27 Feb 2014European Medicines Agency Accepts Marketing Authorization Application for The Medicines Company's Oritavancin27 Feb 2014INVESTOR ALERT: Class Action Lawsuit Against The Medicines Company Announced by Glancy Binkow & Goldberg LLP26 Feb 2014Lifshitz & Miller Law Firm Announces Investigation of Emeritus Corporation, Nu Skin Enterprises, Inc., The Medicines Company, Thoratec Corporation and TriQuint Semiconductor, Inc.25 Feb 2014Ryan & Maniskas, LLP Announces Class Action Lawsuit Against The Medicines Company25 Feb 2014INVESTOR ALERT: Investigation of The Medicines Company Announced by Law Offices of Howard G. Smith19 Feb 2014FDA Accepts Filing of the Medicines Company's New Drug Application for Intravenous Antibiotic Oritavancin With Priority Review19 Feb 2014The Medicines Company to Participate in Upcoming Healthcare Investor Conferences19 Feb 2014The Medicines Company Reports Fourth Quarter and Full Year 2013 Financial Results13 Feb 2014Harwood Feffer LLP Announces Investigation of IPC The Medicines Company13 Feb 2014SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of The Medicines Company - MDCO13 Feb 2014THE MEDICINES COMPANY SHAREHOLDERS NOTICE: Shareholder Rights Law Firm Johnson & Weaver, LLP Announces Investigation of Certain Officers and Directors of The Medicines Company12 Feb 2014The Medicines Company Stock Trading Halted Today12 Feb 2014FDA Advisory Committee Recommends Against Antiplatelet Therapy Cangrelor11 Feb 2014Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of The Medicines Company10 Feb 2014SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of The Medicines Company - MDCO10 Feb 2014ALERT: The Rosen Law Firm Announces Investigation of Securities Fraud Claims Against The Medicines Company --- MDCO06 Feb 2014The Medicines Company to Announce Fourth Quarter and Full Year 2013 Financial Results on Wednesday, February 19, 201406 Feb 2014The Medicines Company to Host Acute Cardiovascular Care Investor and Analyst Meeting on March 705 Feb 2014BARDA Awards Contract Worth up to $90 Million to The Medicines Company/Rempex for Development of Gram-Negative Antibiotic13 Jan 2014FDA Grants QIDP Designation to The Medicines Company's Investigational Antibiotic Carbavance08 Jan 2014The Medicines Company to Participate in Upcoming JP Morgan Healthcare Conference07 Jan 2014Filing Submission & Acceptance, Earnings Release Schedule, Agreement, and Conference Participation - Research Report on The Medicines Company, Covance, Air Methods, Auxilium, and Teleflex

Contact Us

The Medicines Company
8 Sylvan Way
Parsippany, NJ 07054 USA
Tel 973 290 6000
Toll-free 800 388 1183
Global Medical Information

Human Resources
Verification of employment
Tel 973 290 6361
Fax 862 207 6361

Investors Relations

Krishna Gorti, MD
Tel 973 290 6122
krishna.gorti@themedco.com

Media Inquiries

Michael Blash
Tel 973 290 6100
michael.blash@themedco.com